Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6160340 | 0.72 | — | — | |
| SCHEMBL28585875 | 0.70 | HCAR3 (0.43) | CRHBPCRHR2MITFMEN1KMT2A | |
| SCHEMBL7303287 | 0.70 | TSHR (0.37) | CRHBPCRHR2HCAR3HCAR2FDFT1 | |
| SCHEMBL273608 | 0.67 | TSHR (0.39) | MEN1KMT2AHCAR3HCAR2 | |
| SCHEMBL4884144 | 0.67 | TSHR (0.39) | MEN1KMT2AHCAR3HCAR2 | |
| SCHEMBL8876521 | 0.67 | TSHR (0.39) | MEN1KMT2AHCAR3HCAR2 | |
| SCHEMBL11068061 | 0.67 | FDFT1 (0.42) | CRHBPCRHR2MEN1KMT2AFDFT1 | |
| SCHEMBL10566794 | 0.66 | ALDH1A1 (0.51) | MEN1KMT2A | |
| SCHEMBL18316474 | 0.64 | CRHBP (0.44) | CRHBPCRHR2MEN1KMT2AHCAR3 | |
| SCHEMBL2234611 | 0.64 | CRHBP (0.44) | CRHBPCRHR2MEN1KMT2AHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040073045-A1 | Pyrrolidine derivative and process for producing the same | EISAI CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1375479-A9 | PYRROLIDINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | Eisai Co., Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| EP-1375465-A1 | CYCLOOCTANONE DERIVATIVE AND CYCLODECANONE DERIVATIVE, AND USE THEREOF | Eisai Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073045-A1 | Pyrrolidine derivative and process for producing the same | DHPS, SQLE, FDFT1 | CRHBP 3407/4885CRHR2 3759/4885MITF 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.